Psych Vivas · Psychopharmacology — pharmacogenomics
Pharmacogenomics in psychiatry — consultant viva
Fellowship viva on psychiatric PGx actionability, HLA safety, CYP dosing, trial literacy, and commercial panel pitfalls.
On this page & tools
Target exams
Station structure
Time: 8–10 minutes. Depth: consultant teaching registrar. Expect named guidelines (CPIC), HLA alleles, phenotype language, and one nuanced trial point each for GUIDED and PRIME Care.[1][3][6]
Core questions and model points
-
PK vs PD genes? PK changes exposure (CYP ADME); PD changes receptor/transporter effect. Actionable psychiatry PGx is mostly PK + HLA, not PD colour bins.[1][10]
-
Phenotypes? PM, IM, NM, RM, UM from diplotype/activity score; direction: PM → higher parent levels of many substrates; UM → lower levels/failure risk.[1][2]
-
SSRI CPIC? Hicks 2015 CYP2D6/2C19 SSRI dosing; Bousman 2023 expands CYP2D6/2C19/2B6 and rejects routine SLC6A4/HTR2A use for prescribing.[1][2]
-
HLA-B*15:02? SJS/TEN risk with carbamazepine; avoid if positive and drug-naive; Chen screening prevented cases in Taiwan pathway.[3][4]
-
HLA-A*31:01? Broader CBZ hypersensitivity association including European ancestry (McCormack).[5][3]
-
Phenoconversion? Strong 2D6 inhibitors (paroxetine/fluoxetine/bupropion) can make genotypic NM behave like PM.[1][9]
-
Atomoxetine? CYP2D6-guided dosing/levels (Brown CPIC).[8]
-
Trials? GUIDED: combinatorial testing outcome signals with appraisal caveats; PRIME Care: better gene–drug matching, modest/time-limited remission effects.[6][7]
-
TDM? AGNP levels complement genotype as in vivo phenotype.[9]
-
ISPG? Supports CYP2D6/2C19 selected use + HLA for CBZ/OXC; limited PD panel enthusiasm.[10]
Distinctions that score
Score for separating safety HLA decisions from optional MDD combinatorial panels, drug-naive HLA-positive starts from already long-term tolerant patients, and report interpretation as star allele → phenotype → drug-specific action rather than algorithm worship.[1][3][10]
Common fails
Fails include mandating every gene before every antidepressant, claiming SLC6A4 short allele means SSRIs never work, asserting negative HLA-B*15:02 means zero rash risk, and confusing CYP1A2 smoking–clozapine interactions with mandatory genotyping-first for all clozapine starts.[1][3][10]
References
- [1]Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants Clin Pharmacol Ther, 2023.PMID 37032427
- [2]Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors Clin Pharmacol Ther, 2015.PMID 25974703
- [3]Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update Clin Pharmacol Ther, 2018.PMID 29392710
- [4]Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan N Engl J Med, 2011.PMID 21428768
- [5]McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans N Engl J Med, 2011.PMID 21428769
- [6]Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial JAMA, 2022.PMID 35819423
- [7]Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study J Psychiatr Res, 2019.PMID 30677646
- [8]Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy Clin Pharmacol Ther, 2019.PMID 30801677
- [9]Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 Pharmacopsychiatry, 2018.PMID 29390205
- [10]Bousman CA, Bengesser SA, Aitchison KJ, et al. Review and Consensus on Pharmacogenomic Testing in Psychiatry Pharmacopsychiatry, 2021.PMID 33147643